Pull to refresh
Logo
Daily Brief
Following Why Ranks Sign Up
Chiesi acquires KalVista as pharma deepens rare disease push

Chiesi acquires KalVista as pharma deepens rare disease push

Money Moves

Italian drugmaker pays premium for first oral on-demand therapy for hereditary angioedema

April 29th, 2026: Chiesi agrees to acquire KalVista for $1.9 billion

Overview

For decades, people with hereditary angioedema—a genetic condition where the immune system misfires and swells tissues shut, sometimes fatally—had only one option when an attack hit: injecting themselves, often in a panic, to stop swelling that can close the airway. In July 2025, a pill changed that. On Wednesday, Italian drugmaker Chiesi Farmaceutici agreed to buy the pill's maker, KalVista Pharmaceuticals, for about $1.9 billion in cash—the largest acquisition in Chiesi's 90-year history.

The deal pays $27.00 per share, a 36% premium over KalVista's recent price, and hands Chiesi worldwide rights to EKTERLY (sebetralstat), the only oral on-demand therapy for the rare immune disorder. Chiesi is buying into real commercial momentum: EKTERLY generated $49 million in sales in its first nine months on the US market, with the final quarter alone nearly doubling analyst expectations at $35 million against a consensus of $21 million. A pediatric trial called KONFIDENT-KID also posted positive interim Phase 3 results in March 2026 for children aged 2 to 11, pointing toward a potential US regulatory filing in the second half of this year that could meaningfully expand the patient population Chiesi stands to serve.

Why it matters

Roughly 1 in 50,000 people inherit a disease that can swell their throat shut—and now there is a pill, owned by a company willing to spend billions to sell it.

Play on this story Voices Debate Predict

Key Indicators

$1.9B
Deal value
Largest acquisition in Chiesi's history, paid entirely in cash.
36%
Premium paid
Markup over KalVista's recent trading price before the deal was announced.
$27.00
Per-share price
All-cash offer unanimously approved by both boards.
$49M
EKTERLY 2025 revenue
Sales in EKTERLY's first nine months on the US market after its July 2025 launch.
$35M
Q4 2025 EKTERLY sales
Fourth-quarter revenue nearly doubled the $21M analyst consensus, signaling strong commercial uptake.
1 in 50,000
HAE prevalence
Estimated rate of hereditary angioedema, the disease EKTERLY treats.
First
Oral on-demand HAE therapy
Before EKTERLY, attack treatments required injection or infusion.
Q3 2026
Expected close
Subject to KalVista shareholder vote and regulatory review.

Interactive

Exploring all sides of a story is often best achieved with Play.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Log in Sign Up

People Involved

Giuseppe Accogli
Giuseppe Accogli
Leading the largest deal in company history
 Benjamin Palleiko
Benjamin Palleiko
Selling company after one year of commercial sales

Organizations Involved

Chiesi Farmaceutici
Chiesi Farmaceutici
Family-owned pharmaceutical company
Acquirer

Italian drugmaker based in Parma, owned by the founding Chiesi family, with about 7,000 employees and roughly €3 billion in annual revenue.
KalVista Pharmaceuticals
KalVista Pharmaceuticals
Publicly-traded biotech
Target

US-listed biotech, originally spun out of UK research, focused on plasma kallikrein inhibitors for hereditary angioedema and related conditions.

Timeline

  1. Chiesi agrees to acquire KalVista for $1.9 billion

    M&A

    Italian drugmaker offers $27 per share in cash—a 36% premium—in its largest-ever deal, gaining global rights to EKTERLY. Both boards approve unanimously.

  2. Shareholder law firms open fair-price investigations

    Legal

    Halper Sadeh LLC and Ademi LLP each announced investigations into whether KalVista's board obtained adequate consideration for shareholders, citing substantial insider change-of-control benefits triggered by the deal. Such probes are routine following biotech acquisitions at a premium and do not, by themselves, block deal completion.

  3. Jones Trading downgrades KALV to hold; analyst sees no antitrust risk

    Market

    Jones Trading moved KalVista stock to hold after shares surged 39% to $26.67, just below the $27.00 offer price, leaving minimal upside for investors who buy in now. The firm noted it does not anticipate meaningful antitrust risk given Chiesi's limited existing presence in the hereditary angioedema market.

  4. KONFIDENT-KID trial posts positive interim Phase 3 results for children aged 2–11

    Clinical

    KalVista presents interim data from the largest pediatric HAE trial ever conducted at the 2026 Global Angioedema Leadership Conference: 88.9% of attacks were mild or moderate, median time to symptom relief was 1.5 hours, and sebetralstat was well tolerated with no serious adverse events. A US regulatory filing is targeted for Q3 2026.

  5. FDA approves EKTERLY as first oral on-demand HAE therapy

    Regulatory

    The agency clears sebetralstat for adults and adolescents, ending decades in which the only attack treatments were injections or infusions.

  6. Phase 3 KONFIDENT trial reports positive results

    Clinical

    Sebetralstat shows it can stop hereditary angioedema attacks faster than placebo when taken as a pill, setting up regulatory submission.

  7. KalVista lists on NASDAQ

    Corporate

    The biotech becomes publicly traded in the US through a reverse merger, raising capital to push sebetralstat through late-stage trials.

  8. KalVista founded around a single enzyme target

    Company History

    British scientists launch KalVista to develop drugs blocking plasma kallikrein, an enzyme that drives swelling in hereditary angioedema.

Scenarios

Predict which scenario wins. Contrarian picks score more — points lock in when the scenario resolves.

Log in to predict. Track your picks, climb the leaderboard. Log in Sign Up
1

Deal closes on schedule, EKTERLY rolls out worldwide

KalVista shareholders approve the sale, antitrust reviews in the US and EU clear without conditions, and the deal closes in Q3 2026 as planned. Chiesi uses its established commercial infrastructure across Europe and Asia to launch EKTERLY in markets KalVista could not have reached alone for years. Rare-disease prescription drug sales typically grow slowly but durably, so revenue ramps over multiple years rather than a single launch quarter.

Discussed by: Bloomberg, BioSpace, sell-side biotech analysts
Consensus —
2

Competing bidder emerges, forces price up

A larger pharma player—possibly one already active in rare immunology like Takeda, Sanofi, or CSL—decides EKTERLY's franchise potential is worth more than $1.9 billion and tables a topping bid before the shareholder vote. Chiesi's deal includes a customary breakup fee, but the family-owned company has limited ability to win a bidding war against a multinational with deeper pockets. KalVista shareholders end up with a higher price.

Discussed by: M&A arbitrage desks, biotech deal trackers
Consensus —
3

Regulatory review delays close into 2027

EU or US antitrust regulators take a closer look at how the combined company would compete in the small hereditary angioedema market, where only a handful of companies—BioCryst, Takeda, CSL, Pharvaris—operate. Chiesi has limited HAE presence today, so substantive overlap concerns are unlikely, but second-request reviews can still push closing dates by months. The deal closes eventually but later than guided.

Discussed by: Antitrust attorneys, deal-completion analysts
Consensus —
4

Commercial launch underperforms expectations under new owner

Once Chiesi takes over, integration friction or pricing pushback from US payers slows EKTERLY's uptake compared to KalVista's pre-deal projections. Rare disease drugs depend heavily on small specialist networks and patient organizations; if Chiesi's commercial team mishandles those relationships, prescriptions plateau. The deal still pays off long-term but takes longer to break even than planned.

Discussed by: Pharma industry observers, rare disease patient groups
Consensus —

Historical Context

AstraZeneca acquires Alexion (2020)

December 2020

What Happened

AstraZeneca paid $39 billion for Alexion, a Boston-based rare disease specialist whose flagship drug Soliris treated paroxysmal nocturnal hemoglobinuria and other ultra-rare conditions. The deal was AstraZeneca's largest ever and pulled the British-Swedish drugmaker into a category dominated until then by smaller, focused biotechs.

Outcome

Short Term

Alexion became AstraZeneca's rare disease division and immediately added high-margin revenue. Investors who had questioned the price came around as Soliris and its successor Ultomiris kept growing.

Long Term

The deal helped legitimize rare-disease franchises as a strategic acquisition category for big pharma, accelerating subsequent transactions and bidding multiples for orphan-drug companies.

Why It's Relevant Today

Same template as Chiesi-KalVista: a larger pharma company buys a smaller specialist with an approved rare-disease drug to gain instant franchise revenue and global launch capacity. The pricing math—premium for a launched product with limited competition—mirrors what Chiesi paid.

Takeda acquires Shire (2019)

January 2019

What Happened

Japanese drugmaker Takeda completed a $62 billion takeover of Shire, the Ireland-headquartered rare disease leader behind several hereditary angioedema therapies including Firazyr and Takhzyro. It was the largest overseas acquisition by a Japanese company at the time.

Outcome

Short Term

Takeda took on substantial debt to fund the deal and spent years divesting non-core assets. Shire's HAE franchise became a cornerstone of Takeda's rare disease business.

Long Term

Takeda is now one of the dominant players in hereditary angioedema worldwide, the same therapeutic area Chiesi is entering through KalVista. The Shire deal showed both the appeal and the price tag of HAE leadership.

Why It's Relevant Today

Establishes how valuable HAE franchises can be—Takeda paid tens of billions partly for an injection-based portfolio that EKTERLY is now competing against. It also frames who Chiesi will go up against commercially.

Sanofi acquires Bioverativ (2018)

January-March 2018

What Happened

French drugmaker Sanofi paid $11.6 billion for Bioverativ, a Biogen spinoff focused on hemophilia. Like KalVista, Bioverativ had a launched product and a clear path in a rare blood disorder market.

Outcome

Short Term

Sanofi gained a foothold in rare hematology and immediately started a string of further rare-disease deals, signaling a new strategic direction.

Long Term

The acquisition is now seen as a successful template for rare-disease M&A: pay a premium for a smaller company with an approved drug and use the buyer's global infrastructure to scale it.

Why It's Relevant Today

The structural similarity—mid-size acquirer, focused biotech with a launched orphan drug, premium price, expansion into rare disease—is almost identical to Chiesi-KalVista, just at smaller scale. Demonstrates the deal logic Chiesi is following.

Sources

(11)
+5
Bloomberg Chiesi Group BusinessWire BioSpace PR Newswire Investing.com KalVista IR Fierce Pharma MedCity News BusinessWire PR Newswire